Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Berk

Showing results (891-900 of 1,136) with videos related to

Pageof 114
Sort By:
The Journal of Clinical Psychiatry|September 28, 2010
Qualitative methods in early-phase drug trials: broadening the scope of data and methods from an RCT of N-acetylcysteine in schizophreniaMichael Berk, Ahmed Munib, Olivia Dean, et al.
BMC Medicine|February 18, 2019
Correction to: A randomised controlled trial of a mitochondrial therapeutic target for bipolar depression: mitochondrial agents, N-acetylcysteine, and placeboMichael Berk, Alyna Turner, Gin S Malhi, et al.
Psychopharmacology|November 13, 2019
S-Adenosylmethionine (SAMe) monotherapy for depression: an 8-week double-blind, randomised, controlled trialJerome Sarris, Jenifer Murphy, Con Stough, et al.
Frontiers in Pharmacology|July 23, 2021
Cocaine-Induced Changes in Tonic Dopamine Concentrations Measured Using Multiple-Cyclic Square Wave Voltammetry <i>in vivo</i>Jason Yuen, Abhinav Goyal, Aaron E Rusheen, et al.
Preventive Medicine|February 25, 2016
The addition of depression to the Framingham Risk Equation model for predicting coronary heart disease risk in womenAdrienne O'Neil, Aaron J Fisher, Katherine J Kibbey, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry|June 30, 2018
The use of a gene expression signature and connectivity map to repurpose drugs for bipolar disorderSrisaiyini Kidnapillai, Chiara C Bortolasci, Madhara Udawela, et al.
The Journal of Clinical Psychiatry|November 13, 2009
Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapineDavid de Lucena, Brisa Simões Fernandes, Michael Berk, et al.
BMC Medicine|January 26, 2019
A randomised controlled trial of a mitochondrial therapeutic target for bipolar depression: mitochondrial agents, N-acetylcysteine, and placeboMichael Berk, Alyna Turner, Gin S Malhi, et al.
Journal of Affective Disorders|February 1, 2019
Nutraceuticals for major depressive disorder- more is not merrier: An 8-week double-blind, randomised, controlled trialJerome Sarris, Gerard J Byrne, Con Stough, et al.
BMC Medicine|November 16, 2013
DSM-5: a collection of psychiatrist views on the changes, controversies, and future directionsCharles B Nemeroff, Daniel Weinberger, Michael Rutter, et al.
Pageof 114

Showing results (891-900 of 1,136) with videos related to

Sort By:
Pageof 114
The Journal of Clinical Psychiatry|September 28, 2010
Qualitative methods in early-phase drug trials: broadening the scope of data and methods from an RCT of N-acetylcysteine in schizophreniaMichael Berk, Ahmed Munib, Olivia Dean, et al.
BMC Medicine|February 18, 2019
Correction to: A randomised controlled trial of a mitochondrial therapeutic target for bipolar depression: mitochondrial agents, N-acetylcysteine, and placeboMichael Berk, Alyna Turner, Gin S Malhi, et al.
Psychopharmacology|November 13, 2019
S-Adenosylmethionine (SAMe) monotherapy for depression: an 8-week double-blind, randomised, controlled trialJerome Sarris, Jenifer Murphy, Con Stough, et al.
Frontiers in Pharmacology|July 23, 2021
Cocaine-Induced Changes in Tonic Dopamine Concentrations Measured Using Multiple-Cyclic Square Wave Voltammetry <i>in vivo</i>Jason Yuen, Abhinav Goyal, Aaron E Rusheen, et al.
Preventive Medicine|February 25, 2016
The addition of depression to the Framingham Risk Equation model for predicting coronary heart disease risk in womenAdrienne O'Neil, Aaron J Fisher, Katherine J Kibbey, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry|June 30, 2018
The use of a gene expression signature and connectivity map to repurpose drugs for bipolar disorderSrisaiyini Kidnapillai, Chiara C Bortolasci, Madhara Udawela, et al.
The Journal of Clinical Psychiatry|November 13, 2009
Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapineDavid de Lucena, Brisa Simões Fernandes, Michael Berk, et al.
BMC Medicine|January 26, 2019
A randomised controlled trial of a mitochondrial therapeutic target for bipolar depression: mitochondrial agents, N-acetylcysteine, and placeboMichael Berk, Alyna Turner, Gin S Malhi, et al.
Journal of Affective Disorders|February 1, 2019
Nutraceuticals for major depressive disorder- more is not merrier: An 8-week double-blind, randomised, controlled trialJerome Sarris, Gerard J Byrne, Con Stough, et al.
BMC Medicine|November 16, 2013
DSM-5: a collection of psychiatrist views on the changes, controversies, and future directionsCharles B Nemeroff, Daniel Weinberger, Michael Rutter, et al.
Pageof 114